nanotech-investing Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
nanotech-investing Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
nanotech-investing Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
nanotech-investing Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
nanotech-investing Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
nanotech-investing Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
nanotech-investing Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology Annual Meeting
nanotech-investing Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
nanotech-investing Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
SAGA Metals Achieves 100% Drilling Success in 2025-Reports Final Assays from Trapper South at Radar Critical Minerals Project in Labrador
